

Foundation Medicine, Inc.  
Form 8-K  
April 03, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): April 3, 2014**

**Foundation Medicine, Inc.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State or other jurisdiction of**  
**incorporation)**

**001-36086**  
**(Commission File Number)**

**27-1316416**  
**(I.R.S. Employer**  
**Identification No.)**

**150 Second Street**

**Cambridge, MA**  
**(Address of principal executive offices)**

**02141**  
**(Zip Code)**

Registrant's telephone number, including area code **(617) 418-2200**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On April 3, 2014, Foundation Medicine, Inc. issued a press release announcing the expansion of its ongoing collaboration with Clovis Oncology, Inc. to develop a novel Premarket Approval (PMA) companion diagnostic test.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Foundation Medicine, Inc., dated April 3, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**FOUNDATION MEDICINE, INC.**

Date: April 3, 2014

By: /s/ Robert W. Hesslein  
Robert W. Hesslein

Senior Vice President, General Counsel and  
Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued by Foundation Medicine, Inc. dated April 3, 2014.